T-cell engaging bispecific antibodies (T-biAbs) mediate potent and selective cytotoxicity by combining specificities for target and effector cells in one molecule. Chemically programmed T-biAbs (cp-T-biAbs) are precisely assembled compositions of (i) small molecules that govern cancer cell surface targeting with high affinity and specificity and (ii) antibodies that recruit and activate T cells and equip the small molecule with confined biodistribution and longer circulatory half-life. Conceptually similar to cp-T-biAbs, switchable chimeric antigen receptor T cells (sCAR-Ts) can also be put under the control of small molecules by using a chemically programmed antibody as a bispecific adaptor molecule. As such, cp-T-biAbs and cp-sCAR-Ts can endow small molecules with the power of cancer immunotherapy. We here review the concept of chemically programmed antibodies for recruiting and activating T cells as a promising strategy for broadening the utility of small molecules in cancer therapy.

T 细胞结合双特异性抗体 (T-biAbs) 通过将靶细胞和效应细胞的特异性结合在一个分子中来介导有效和选择性的细胞毒性。化学程序化的 T-biAb (cp-T-biAb) 是由 (i) 以高亲和力和特异性控制癌细胞表面靶向的小分子和 (ii) 募集和激活 T 细胞并为小分子配备有限的生物分布和更长的循环半衰期。在概念上与 cp-T-biAbs 相似，可切换嵌合抗原受体 T 细胞 (sCAR-Ts) 也可以通过使用化学程序化抗体作为双特异性衔接分子来置于小分子的控制之下。因此，cp-T-biAbs和cp-sCAR-Ts可以赋予小分子癌症免疫治疗的力量。